- Johnson & Johnson stock price today and history
Please, Signup (Login) to subscribe or trade (demo)
Johnson & Johnson stock price, JNJ
Johnson & Johnson stock chart:
Johnson & Johnson close price: 121.76
Stock price forecast:
DOWN TO -5.13%
Total forecasts: 81
Reached: 24 (29.63%)
Total Win: 61.42 (53.77%)
Showing 1-10 of 533 items.
|Date of Forecast||Stock Price||Target Price||Forecast Reached Date|
Johnson & Johnson latest news:
Johnson & Johnson, Goldman sneeze and stocks catch a cold
US stocks fall, with health care and bank stocks down the most after poor first-quarter results from Johnson & Johnson and Goldman Sachs
Goldman Sachs, J&J pull Wall Street lower
NEW YORK (Reuters) - The S&P 500 fell for the fourth time in five sessions on Tuesday, weighed down by a drop in Goldman Sachs and Johnson & Johnson following their quarterly results, while geopolitical tensions added to investor caution.
Wall St. loses ground as Goldman, J&J slump
NEW YORK (Reuters) - The S&P 500 fell for the fourth time in five sessions on Tuesday, weighed down by declines in Goldman Sachs and Johnson & Johnson following their quarterly results, while geopolitical tensions added to investor caution.
U.S. stocks closer lower as Goldman, J&J disappoint with their results
U.S. stocks closed lower on Tuesday, pressured after a number of key companies disappointed with their quarterly results, renewing concerns that the market's valuation may not be supported by economic activity. The Dow Jones Industrial Average fell 113 points, or 0.6%, to 20,524. The S&P 500 lost 6.8 points to 2,342, a drop of 0.3%. The Nasdaq Composite Index fell 7 points to 5,849, a drop of 0.1%. Among the biggest drags on the day was Goldman Sachs Group Inc. , which fell 4.7% after its results fell short of analyst forecasts. Johnson & Johnson lost 3.1%; the company posted a drop in sales in the first quarter. Both are Dow components, accounting for the outsized loss in the blue-chip average. Separately, Netflix Inc. shed 2.6% on concerns about the company's ability to attract and retain new users. While major indexes ended off their lows of the session, market participants have been looking to corporate earnings to justify a multimonth rally in equities that had taken stock benchmarks to repeated records, though the rally has stalled as doubts about valuations pile up and amid concerns over President Donald Trump's ability to quickly implement his economic agenda.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Wall Street falls as Goldman, J&J weigh
NEW YORK (Reuters) - U.S. stocks declined on Tuesday, weighed down by a drop in Goldman Sachs and Johnson & Johnson in the wake of their quarterly results, while geopolitical tensions continued to fuel investor caution.
Sharp losses for health care stocks, banks pull indexes down
US stocks are falling as Johnson & Johnson and Cardinal Health put pressure on health care companies and weak results from Goldman Sachs affect banks
Wall Street down as Goldman, J&J's results disappoint
(Reuters) - U.S. stocks fell further in midday trading on Tuesday as corporate heavyweights Goldman Sachs and Johnson & Johnson disappointed investors with their quarterly results, while geopolitical tensions continued to weigh on market sentiment.
J&J first quarter revenue misses estimates; new forecast includes Actelion
(Reuters) - Johnson & Johnson on Tuesday reported disappointing pharmaceutical and consumer product sales as revenue missed analyst estimates, sending its shares sharply lower.
Weak Goldman, J&J results drag down Wall Street
(Reuters) - U.S. stocks drifted lower on Tuesday as corporate heavyweights Goldman Sachs and Johnson & Johnson disappointed investors with their quarterly results, while geopolitical tensions continued to weigh on market sentiment.
Why Johnson & Johnson Raised Guidance After Missing Sales Estimates
Stocks close fractionally higher as ECB stands pat on easing
U.S. stocks finished slightly higher Thursday after European Central Bank President Mario Draghi left easing measures in place but downplayed deflation concerns. The Dow Jones Industrial Average advanced 2.46 points to finish at 20,858.19 led higher by shares of Johnson & Johnson Inc. . The S&P 500 index closed up 1.89 points, or just under 0.1%, at 2,364.87, as health-care and energy stocks gained. The Nasdaq Composite index finished up 1.25 points at 5,838.81.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Johnson & Johnson wins trial in talc product liability lawsuits
- Johnson & Johnson said on Friday that a state court jury in Missouri had returned a verdict in its favor in the latest trial to arise out of thousands of lawsuits alleging the company's talc-based products can increase the risk of ovarian cancer.
Stocks of manufacturers whose CEOs are meeting Trump mostly lower, led by US Steel
The stocks of the manufacturing companies which were meeting with President Donald Trump Thursday were trading mostly lower. The drop comes amid reports that an infrastructure spending plan may be delayed until next year, and tax reform pushed back until at least the summer. United States Steel Corp. led the decliners, falling 6.7% in mid-morning trade. Caterpillar Inc. fell 2.4%, and Emerson Electric Co. fell 1.7%. Lockheed Martin Corp. and Corning Inc. were all down 0.7%. GE was down 0.5%, Whirlpool Corp. was down 0.4% and Dow Chemical Co. was down 0.3%. Goldman Sachs Group Inc. shares were trading down 0.7%. Goldman and Caterpillar combined were shaving about 30 points off the Dow Jones Industrial Average . Trump introduced Goldman's ex-COO Gary Cohn, now National Economic Council director, to the group as "Gary from Goldman." The only two stocks to gain were Johnson & Johnson and International Paper Co. , which were both up less than 1%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
Johnson & Johnson refills drug cabinet with $30 billion Actelion deal
ALLSCHWIL, Switzerland (Reuters) - U.S. healthcare giant Johnson & Johnson will buy Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline, the companies said on Thursday.
Johnson & Johnson agrees $30bn deal for Actelion
Founder Jean-Paul Clozel to head up standalone spin-off research company
Johnson & Johnson to buy Actelion for $30bn
Swiss biotech group’s founder to head up standalone spin-off research company
Johnson & Johnson to Acquire Actelion for $30 Billion
The acquisition of the Swiss biotechnology company will improve Johnson & Johnson’s portfolio of drugs to treat rare diseases.
Johnson & Johnson to buy Actelion for $30 billion, spin off R&D unit
ZURICH (Reuters) - U.S. healthcare giant Johnson & Johnson will acquire Swiss biotech company Actelion in a $30 billion all-cash deal that includes spinning off Actelion's research and development pipeline, the companies said on Thursday.
Johnson & Johnson Opens 2017 on a Cautious Note
The healthcare conglomerate forecast lower revenue and earnings growth than investors had hoped.
Jones Lang LaSalle IncorporatedJLL
Journal Media GroupJMG
Joy Global Inc.JOY
JP Energy Partners LPJPEP
JPMorgan China Region FundJFC
Jumei International Holding LimitedJMEI
Jupai Holdings LimitedJP